HSBC Starts Teva Pharma (TEVA) at Buy, 'innovative medicine division to become a driver of growth'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to HSBC Starts Teva Pharma (TEVA) at Buy, 'innovative medicine division to become a driver of growth'

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

December 14, 2023 8:30 AM EST

Biolojics BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases. Agreement builds on Teva's Pivot to Growth strategy to step up innovation on Teva's innovative pipeline. Teva to obtain exclusive worldwide rights to develop and commercialize BD9 multibody for potential treatment for Atopic Dermatitis and Asthma

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform... More